5-hydroxy-6-8-11-14-eicosatetraenoic-acid and tartaric-acid

A lipid-rich extract, prepared by supercritical fluid (CO2) extraction of freeze-dried stabilized NZ green-lipped mussel powder (Lyprinol) has shown significant anti-inflammatory (AI) activity when given to animals and humans. When treated p.o. with Lyprinol, Wistar and Dark Agouti rats developed neither adjuvant-induced polyarthritis or collagen(II)-induced auto-allergic arthritis. This was achieved with doses < NSAIDs, and 200 times < of other seed or fish oils. Lyprinol subfractions inhibited LTB4 biosynthesis by PMN in vitro, and PGE2 production by activated macrophages. Much of this AI activity was associated with omega-3 PUFAs and natural antioxidants [e.g. carotenoids]. In contrast to NSAIDs, Lyprinol is non-gastro toxic in disease-stressed rats at 300 mg/kg p.o., and does not affect platelet aggregation [human, rat]. Clinical studies, either controlled or randomized, have demonstrated very significant AI activity in patients with osteoarthritis (OA), rheumatoid arthritis (RA), asthma, and other inflammatory conditions. Lyprinol is a reproducible, stable source of bioactive lipids with much greater potency than plant/marine oils currently used as nutritional supplements to ameliorate signs of inflammation.

Topics: Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Arthritis, Rheumatoid; Asthma; Bivalvia; Clinical Trials as Topic; Double-Blind Method; Drug Administration Routes; Drug Evaluation, Preclinical; Drug Stability; Freeze Drying; Humans; Hydroxyeicosatetraenoic Acids; Leukotrienes; Lipids; Lipoxygenase Inhibitors; Medicine, Traditional; Neutrophils; New Zealand; Osteoarthritis; Plant Oils; Preservatives, Pharmaceutical; Randomized Controlled Trials as Topic; Rats; Rats, Wistar; Tartrates; Tissue Extracts; Treatment Outcome